BTK and B-cell chronic lymphocytic leukemia: Although IL15 has been used in studies to understand the impact of BTK inhibition in CLL, this is the first time that DNA methylation of IL15 has been shown to be a potential marker of progression/resistance to acalabrutinib treatment.